| Compound |
Company |
Primary Therapeutical Area / Indication |
Drug development |
|
| Desmoteplase |
|
Heart and Blood Diseases / Stroke |
Phase III
|
 |
|
|
| Vernakalant |
|
Heart and Blood Diseases / Atrial Fibrillation |
Phase III
|
 |
|
|
| YM150 |
|
Heart and Blood Diseases / Venous Thromboembolism |
Phase III
|
 |
|
|
| BI-204 |
|
Heart and Blood Diseases / Atherosclerosis |
Phase II
|
 |
|
|
| EV-077 |
Evolva A/S
|
Heart and Blood Diseases / Thrombosis |
Phase II
|
 |
|
|
| RG1512 |
|
Heart and Blood Diseases / Acute Coronary Syndrome |
Phase II
|
 |
|
|
| Danegaptide |
|
Heart and Blood Diseases / Arrhythmias, Cardiac |
Phase I
|
 |
|
|
| RESP-3000 |
|
Heart and Blood Diseases / Hypertension |
Pre-clinical
|
 |
|
|
| Tacrolimus |
|
Immune System Diseases / Dermatitis, Atopic |
Phase IV
|
 |
|
|
| LCP-Tacro™ |
Veloxis Pharmaceuticals A/S
|
Immune System Diseases / Kidney Transplantation |
Phase III
|
 |
|
|
| Laquinimod |
|
Immune System Diseases / Multiple Sclerosis |
Phase III
|
 |
|
|
| SLITone(TM) Birch |
|
Immune System Diseases / Rhinitis, Allergic, Seasonal |
Phase III
|
 |
|
|
| Anti-NKG2D |
|
Immune System Diseases / Arthritis, Rheumatoid |
Phase II
|
 |
|
|
| DPK-060 |
|
Immune System Diseases / Dermatitis, Atopic |
Phase II
|
 |
|
|
| IBsolvMIR® |
|
Immune System Diseases / Diabetes Mellitus, Type 1 |
Phase II
|
 |
|
|
| Paquinimod (57-57) |
|
Immune System Diseases / Systemic Sclerosis |
Phase II
|
 |
|
|
| RhuDex |
|
Immune System Diseases / Arthritis, Rheumatoid |
Phase II
|
 |
|
|
| US SLIT Cat Hair |
|
Immune System Diseases / Rhinitis, Allergic, Perennial |
Phase II
|
 |
|
|
| Anti-C5aR |
|
Immune System Diseases / Arthritis, Rheumatoid |
Phase I
|
 |
|
|
| Anti-IL21 |
|
Immune System Diseases / Arthritis, Rheumatoid |
Phase I
|
 |
|
|